H. Lundbeck A/S (OTCMKTS:HLUYY) Hits New 12-Month Low at $25.77

H. Lundbeck A/S (OTCMKTS:HLUYY)’s stock price hit a new 52-week low during trading on Tuesday . The company traded as low as $25.77 and last traded at $25.77, with a volume of 985 shares traded. The stock had previously closed at $26.24.

A number of equities analysts have recently commented on the stock. Berenberg Bank assumed coverage on shares of H. Lundbeck A/S in a research report on Wednesday. They set a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of H. Lundbeck A/S in a research report on Thursday, October 7th. Zacks Investment Research raised shares of H. Lundbeck A/S from a “hold” rating to a “buy” rating and set a $31.00 target price on the stock in a research report on Wednesday, October 20th. Credit Suisse Group reaffirmed an “underperform” rating on shares of H. Lundbeck A/S in a research report on Friday, August 20th. Finally, Barclays reissued an “overweight” rating on shares of H. Lundbeck A/S in a report on Thursday, September 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $30.84.

The company has a market capitalization of $5.13 billion, a PE ratio of 15.71 and a beta of 0.69. The company’s fifty day moving average is $27.34 and its 200-day moving average is $29.64. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.97 and a quick ratio of 0.66.

H. Lundbeck A/S Company Profile (OTCMKTS:HLUYY)

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Its product portfolio targets the following diseases: Alzheimer’s, depression, Parkinson’s, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington’s.

Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers

Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.